Ab­b­Vie is go­ing for it in cys­tic fi­bro­sis. But why are they buy­ing the weak Gala­pa­gos port­fo­lio in a $245M deal?

Ab­b­Vie took a hard look at some weak da­ta for Gala­pa­gos’ $GLPG dou­ble and triple for cys­tic fi­bro­sis — and de­cid­ed to buy the lot.

We al­ready knew that the Phase II study of the C2 cor­rec­tor GLPG2737 com­bined with Orkam­bi didn’t work all that well. Now new da­ta from Gala­pa­gos help prove that adding it to their GLPG2451 and GLPG2222 drugs did noth­ing at all to im­prove re­sults.

The dou­ble alone pro­duced “a mean in­crease in ppFEV1 of ap­prox­i­mate­ly 3%.” The triple did no bet­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER